TY - JOUR
T1 - Structural bone allograft in pediatric foot surgery.
AU - Nowicki, Philip D.
AU - Tylkowski, Chester M.
AU - Iwinski, Henry J.
AU - Talwalkar, Vishwas
AU - Walker, Janet L.
AU - Milbrandt, Todd A.
PY - 2010/5
Y1 - 2010/5
N2 - Structural bone allografts are used in a variety of surgical procedures, but only a few investigators have examined their use and associated complications in the pediatric population specifically. In a retrospective review of pediatric foot procedures, we sought to determine types and rates of complications associated with structural bone allografts as well as time to incorporation of these allografts. Minimum follow-up was 12 months. Eighteen patients with 31 structural allografts were reviewed. The total complication rate was 7.1%, and the allograft incorporation rate was 90% (mean time after surgery, 9 months). Mean follow-up was 22 months. There were no pseudarthroses, nonunions, or fractures at the bone-graft sites. Structural bone allografts can be safely used in foot procedures in pediatric neuromuscular patients without major risk for complications, and their use can reduce autograft-harvest morbidity in pediatric patients with neuromuscular conditions.
AB - Structural bone allografts are used in a variety of surgical procedures, but only a few investigators have examined their use and associated complications in the pediatric population specifically. In a retrospective review of pediatric foot procedures, we sought to determine types and rates of complications associated with structural bone allografts as well as time to incorporation of these allografts. Minimum follow-up was 12 months. Eighteen patients with 31 structural allografts were reviewed. The total complication rate was 7.1%, and the allograft incorporation rate was 90% (mean time after surgery, 9 months). Mean follow-up was 22 months. There were no pseudarthroses, nonunions, or fractures at the bone-graft sites. Structural bone allografts can be safely used in foot procedures in pediatric neuromuscular patients without major risk for complications, and their use can reduce autograft-harvest morbidity in pediatric patients with neuromuscular conditions.
UR - http://www.scopus.com/inward/record.url?scp=77957262181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957262181&partnerID=8YFLogxK
M3 - Article
C2 - 20567741
AN - SCOPUS:77957262181
SN - 1078-4519
VL - 39
SP - 238
EP - 240
JO - American journal of orthopedics (Belle Mead, N.J.)
JF - American journal of orthopedics (Belle Mead, N.J.)
IS - 5
ER -